EMPLOYMENT AGREEMENTEmployment Agreement • July 13th, 2016 • Motif Bio PLC • Pharmaceutical preparations
This Employment Agreement (this “Agreement”) is effective as of May 1, 2016 (the “Effective Date”), and is entered into by and between Motif BioSciences Inc. (the “Company”), and Pete A. Meyers (“Employee”) (collectively with the Company, the “Parties”; each of the Parties referred to individually as a “Party”).
AGREEMENT AND PLAN OF MERGER by and among MOTIF BIOSCIENCES INC., MOTIF BIO PLC, MOTIF ACQUISITION SUB INC., and STEPHEN AUSTIN, as Motif UK Sole Shareholder dated as of March 27, 2015Agreement and Plan of Merger • July 13th, 2016 • Motif Bio PLC • Pharmaceutical preparations • Delaware
SERVICE AGREEMENTService Agreement • July 13th, 2016 • Motif Bio PLC • Pharmaceutical preparations • England and Wales
CONSULTANCY AGREEMENTConsultancy Agreement • July 13th, 2016 • Motif Bio PLC • Pharmaceutical preparations • England and Wales
Sale and Purchase AgreementSale and Purchase Agreement • July 13th, 2016 • Motif Bio PLC • Pharmaceutical preparations
This Sale and Purchase Agreement (the “Agreement”), entered into on September 13, 2013 (the “Effective Date”), by Life Sciences Management Group, Inc. (a Maryland Corporation, the “Purchaser) with offices at 7272 Wisconsin Ave, Suite 300, Bethesda, MD 20814, and Acino Pharma AG, with offices at Dornacherstrasse 114, CH-4147 Aesch, Switzerland, (the “Company”)
AGREEMENT AND PLAN OF MERGER BY AND AMONG NUPRIM, INC., (a Maryland corporation) NUPRIM SHAREHOLDERS, MOTIF BIOSCIENCES INC., (a Delaware corporation) AND R. MICHAEL FLOYD AS NUPRIM SHAREHOLDERS’ REPRESENTATIVE DATED AS OF December 31, 2014Agreement and Plan of Merger • July 13th, 2016 • Motif Bio PLC • Pharmaceutical preparations • Delaware
This AGREEMENT AND PLAN OF MERGER (together with all Schedules and Exhibits, this “Agreement”), dated as of December 31, 2014, is entered into by and among Motif Biosciences Inc., a Delaware corporation (“Motif”), Nuprim, Inc., a Maryland corporation (“Nuprim”), and each of R. Michael Floyd, Khalid Islam, Brad Spellberg, and Sergio Lociuro (collectively the “Nuprim Shareholders” and each a “Nuprim Shareholder”) as the shareholders of Nuprim. Additionally, this Agreement is joined by R. Michael Floyd in his representative capacity as Nuprim Shareholders’ Representative. Motif, Nuprim, Nuprim Shareholders and Nuprim Shareholders’ Representative are each referred to herein as a “Party” and collectively as, the “Parties”.
SALE AND PURCHASE AGREEMENTSale and Purchase Agreement • July 13th, 2016 • Motif Bio PLC • Pharmaceutical preparations
Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, USA “ROCHE NUTLEY”, both, ROCHE BASEL and ROCHE NUTLEY jointly called SELLER”)
ADVISORY AND CONSULTANCY AGREEMENTAdvisory and Consultancy Agreement • July 13th, 2016 • Motif Bio PLC • Pharmaceutical preparations • England and Wales
